Akèy › Metiyè › Bioengineers and Biomedical Engineers › Dallas, TX
Bioengineers and Biomedical Engineers nan Dallas, TX: Salè H-1B
31 aplikasyon kondisyon travay pou okipasyon sa a ak yon sit travay nan Dallas, TX. Salè baz medyàn ofri $81,600; mwatye mitan $62,181–$125,000.
Demann (LCA)31
Salè medyan ofri$81,600
Mwatye salè yo$62,181–$125,000
10yèm–90yèm pousantaj$55,182–$127,130
Pa nivo salè
| Nivo revni | Salè medyan |
|---|---|
| Nivo I (antre) | $61,428 |
| Nivo II (kalifye) | $80,000 |
| Nivo III (eksperyans) | $125,000 |
| Nivo IV (plen kompetans) | $125,216 |
Depatman Travay la etabli kat nivo salè prevanlan pou chak okipasyon ak zòn, soti nan Nivo I (antre) rive nan Nivo IV (plen kompetans). Anplwayè a chwazi nivo ki koresponn ak kondisyon travay la.
Anplwayè yo
| Anplwayè | LCA | Salè medyan |
|---|---|---|
| UT Southwestern Medical Center | 16 | $64,591 |
| Colossal Biosciences, Inc. | 5 | $125,000 |
| Spectral MD, Inc. | 2 | $103,632 |
| Crown Laboratories, Inc. | 1 | $62,130 |
| Cannon Design, Inc. | 1 | $81,600 |
| Dallas Medical Center, LLC | 1 | $65,000 |
| BackStop Neural, Inc. | 1 | $125,000 |
| Osteal Therapeutics, LLC | 1 | $125,216 |
| Texas Scottish Rite Hospital for Children | 1 | $68,786 |
| Phenome Technologies Inc | 1 | — |
| Philips DS North America, LLC | 1 | $125,216 |
Tit travay
- Scientist, Genome Engineering4
- Research Engineer4
- Postdoctoral Researcher4
- Assistant Professor3
- Agreement Compliance Manager3
- Clinical Research Scientist1
- Medical Equipment Planner1
- Biomedical Quality Engineer II1
- Associate, Genome Engineering1
- Senior Biomedical Engineering Specialist1
- Research Associate1
- Biomedical Engineer I1
- VP of Engineering1
- Engineering Program Lead, NPD1
- Biomechanical Engineer1
Salè yo se fen ki pi ba nan salè yo ofri sou chak aplikasyon, konvèti nan yon montan anyèl; estatistik yo itilize sèlman aplikasyon tan plen sètifye. Yon LCA pa yon apwobasyon visa epi yon sèl LCA ka kouvri plizyè pozisyon. Sous: Depatman Travay Etazini, Done Divulgasyon LCA OFLC, ane fiskal 2023–2026 (dènye desizyon Jun 30, 2026).